{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T18:09:41Z","timestamp":1778350181435,"version":"3.51.4"},"reference-count":89,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2664332","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T17:24:57Z","timestamp":1778347497000},"page":"1445-1461","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the US"],"prefix":"10.1080","volume":"29","author":[{"given":"Tyler","family":"Mantaian","sequence":"first","affiliation":[{"name":"HEOR, Lumanity","place":["Morristown, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Gillard","sequence":"additional","affiliation":[{"name":"GHEOR Neuroscience, Bristol Myers Squibb","place":["Princeton, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Kowalski","sequence":"additional","affiliation":[{"name":"HEOR, Lumanity","place":["Morristown, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kramer","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Neuroscience, Bristol Myers Squibb","place":["Princeton, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew F.","family":"Sidovar","sequence":"additional","affiliation":[{"name":"GHEOR Neuroscience, Bristol Myers Squibb","place":["Princeton, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Cutler","sequence":"additional","affiliation":[{"name":"Psychiatry and Neuroscience, SUNY Upstate Medical University","place":["Syracuse, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"National Institute of Mental Health. Schizophrenia 2022. [2025 Sep 19]. Available from: https:\/\/www.nimh.nih.gov\/health\/statistics\/schizophrenia."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxn001"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14458"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1801490"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249532"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2010.10.002"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S117321"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01000-1"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026616666160608084834"},{"issue":"5","key":"e_1_3_5_12_1","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"Muench J","year":"2010","unstructured":"Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617\u2013622.","journal-title":"Am Fam Physician"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20579"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.695"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v2.i5.74"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-12-20"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-021-00348-0"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X226050"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.25.1.037"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-50"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.6.509"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-017-0071-9"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2022.2092402"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2024.08.001"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00632"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20240076"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21101083"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.SU21024IP1"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017015"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24m15497"},{"key":"e_1_3_5_31_1","unstructured":"Tice JA Whittington MD McKenna A et al. KarXT for schizophrenia: effectiveness and value; final evidence report: institute for clinical and economic review. 2024 [2025 Sep 19]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2024\/03\/ICER_Schizophrenia_Final-Evidence-Report_12-Month-Update.pdf."},{"issue":"4","key":"e_1_3_5_32_1","first-page":"185","article-title":"Cost-effectiveness analysis of aripiprazole once-monthly for the treatment of schizophrenia in the UK","volume":"18","author":"Tempest M","year":"2015","unstructured":"Tempest M, Sapin C, Beillat M, et al. Cost-effectiveness analysis of aripiprazole once-monthly for the treatment of schizophrenia in the UK. J Ment Health Policy Econ. 2015;18(4):185\u2013200.","journal-title":"J Ment Health Policy Econ"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.02.008"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802507547"},{"key":"e_1_3_5_35_1","unstructured":"Kuipers E Kendall T Udechuku A et al. Psychosis and schizophrenia in adults; National Clinical Guideline Number 178: National Institiute for Health and Care Excellence. 2014. [2024 Dec 16]. Available from: https:\/\/www.nice.org.uk\/guidance\/cg178."},{"issue":"10","key":"e_1_3_5_36_1","article-title":"CADTH reimbursement review: cariprazine (Vraylar)","volume":"2","author":"Allergan","year":"2022","unstructured":"Allergan. CADTH reimbursement review: cariprazine (Vraylar). Can J Health Technol. 2022;2(10).","journal-title":"Can J Health Technol"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18com12123"},{"key":"e_1_3_5_38_1","unstructured":"Novartis. CLOZARIL\u00ae (clozapine). FDA highlights of prescribing information. 1989. [2024 Aug 23]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/019758s073lbl.pdf."},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"e_1_3_5_40_1","volume-title":"Poster presented at Psych Congress,","author":"Kaul I","year":"2024","unstructured":"Kaul I, Sauder C, Sawchak S, et al. Long-term safety, tolerability, and efficacy of xanomeline and trospium chloride in people with schizophrenia: results from the 52-week, open-label EMERGENT-4 trial. Poster presented at Psych Congress, 2024 Oct 29\u2013Nov 2; Boston, MA."},{"key":"e_1_3_5_41_1","volume-title":"Poster presented at Psych Congress,","author":"Kaul I","year":"2024","unstructured":"Kaul I, Sauder C, Sawchak S, et al. Long-term safety, tolerability, and efficacy of xanomeline and trospium chloride in people with schizophrenia: results from the 52-week, open-label EMERGENT-5 trial. Poster presented at Psych Congress, 2024 Oct 29\u2013Nov 2; Boston, MA."},{"key":"e_1_3_5_42_1","volume-title":"Poster presented at Psych Congress,","author":"Hickey C","year":"2024","unstructured":"Hickey C, Sidovar MF, Garcia A, et al. Comparative efficacy, safety, and tolerability of xanomeline and trospium chloride versus eight atypical antipsychotics for the acute treatment of adults with schizophrenia. Poster presented at Psych Congress, 2024 Oct 29\u2013Nov 2; Boston, MA."},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.539528"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000111245.75752.C6"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1029736"},{"issue":"12","key":"e_1_3_5_46_1","article-title":"Provisional life expectancy estimates for January through June, 2023: national vital statistics reports","volume":"72","author":"Arias E","year":"2023","unstructured":"Arias E, Tejada-Vera B, Ahmad F, et al. Provisional life expectancy estimates for January through June, 2023: national vital statistics reports. Natl Center Health Stat. 2023;72(12).","journal-title":"Natl Center Health Stat"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.177.3.212"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2018.0060"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2010.198507"},{"key":"e_1_3_5_50_1","unstructured":"Merative Micromedex. REDBOOK 2024. 2024. [Dec 16]. Available from: https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/."},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.841705"},{"key":"e_1_3_5_52_1","unstructured":"Centers for Medicare & Medicaid Services. Physician fee schedule look-up tool 2024. 2024. [Dec 16]. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search."},{"key":"e_1_3_5_53_1","unstructured":"US Bureau of Labor and Statistics. Consumer price index for all urban consumers (CPI-U). 2024. [2025 Jan 17]. Available from: https:\/\/data.bls.gov\/dataViewer\/view\/timeseries\/CUSR0000SAM."},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02650-y"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.05.014"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-105"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.2022918"},{"issue":"1607","key":"e_1_3_5_58_1","article-title":"Reference case guidelines for benefit-cost analysis in global health and development","volume":"3","author":"Robinson LA","year":"2019","unstructured":"Robinson LA, Hammitt JK, O\u2019Keeffe L. Reference case guidelines for benefit-cost analysis in global health and development. Gates Open Res. 2019;3(1607).","journal-title":"Gates Open Res"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.25.7.810"},{"key":"e_1_3_5_60_1","unstructured":"Centers for Medicare & Medicaid Services. HHS announces 15 additional drugs selected for medicare drug price negotiations in continued effort to lower prescription drug costs for seniors. 2025. [2025 Feb 19]. Available from: https:\/\/www.cms.gov\/newsroom\/press-releases\/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lower."},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.987408"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.4383"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.09.019"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2007.03.002"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.12.487"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000246215.49271.b8"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.05.002"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006633.pub2"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S348143"},{"key":"e_1_3_5_70_1","unstructured":"AbbVie. VRAYLAR\u00ae (cariprazine). FDA highlights of prescribing information. 2024. [2024 Dec 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/204370lbl.pdf."},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4450-3"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.10.015"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1459-z"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000979"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.14101275"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw076"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy002"},{"key":"e_1_3_5_78_1","unstructured":"Intra-Cellular Therapies. Most common adverse reactions. 2025. [2025 Jan 17]. Available from: https:\/\/www.caplytahcp.com\/schizophrenia\/weight-metabolics."},{"key":"e_1_3_5_79_1","unstructured":"Intra-Cellular Therapies. Intra-cellular therapies announces positive topline results in phase 3 trial evaluating CAPLYTA for the prevention of relapse in patients with schizophrenia. 2024. [2025 Jan 17]. Available from: https:\/\/ir.intracellulartherapies.com\/news-releases\/news-release-details\/intra-cellular-therapies-announces-positive-topline-results-2."},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.64719\/pb.4372"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830130055011"},{"key":"e_1_3_5_82_1","unstructured":"Bristol Myers-Squibb. COBENFY (xanomeline and trospium chloride). FDA Highlights of Prescribing Information 2024. 2025. [Jan 20]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216158s000lbl.pdf."},{"key":"e_1_3_5_83_1","unstructured":"Otsuka. ABILIFY\u00ae (aripiprazole) FDA highlights of prescribing information. 2002. [2024 Dec 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021436s038 021713s030 021729s022 021866s023lbl.pdf."},{"key":"e_1_3_5_84_1","unstructured":"Eli Lilly. ZYPREXA (olanzapine) FDA highlights of prescribing information. 1996. [2024 Dec 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020592s062021086s040021253s048lbl.pdf."},{"key":"e_1_3_5_85_1","unstructured":"Janssen. RISPERDAL\u00ae (risperidone). FDA highlights of prescribing information. 1993. [2024 Dec 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/020272s085 020588s072 021444s058lbl.pdf."},{"key":"e_1_3_5_86_1","unstructured":"Otsuka. REXULTI\u00ae (brexpiprazole). FDA highlights of prescribing information. 2015. [2024 Dec 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/205422s003lbl.pdf."},{"key":"e_1_3_5_87_1","unstructured":"Intra-Cellular Therapies. CAPLYTA (lumateperone). FDA highlights of prescribing information. 2019. [2024 Dec 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209500s000lbl.pdf."},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1089\/met.2008.0070"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci23-0085"},{"issue":"3","key":"e_1_3_5_90_1","first-page":"e86","article-title":"Medical care costs among patients with established cardiovascular disease","volume":"16","author":"Nichols GA","year":"2010","unstructured":"Nichols GA, Bell TJ, Pedula KL, et al. Medical care costs among patients with established cardiovascular disease. Am J Manag Care. 2010;16(3):e86\u2013e93.","journal-title":"Am J Manag Care"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2664332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T17:25:00Z","timestamp":1778347500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2664332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2664332"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2664332","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}